For several reasons, ovarian cancer is an excellent malignancy to consider the use of
'targeted'therapeutic strategies. However, to date, despite considerable effort, there remains …

Using targeted agents in ovarian cancer, we are discovering not only how these novel
therapies work but are also unveiling the complex 'wiring'of the disease itself, and the …

Epithelial ovarian cancer remains the most lethal gynecologic malignancy. During the last
15 years, there has been only marginal improvement in 5 year overall survival. These …

Despite recent advances in the treatment of ovarian cancer, a large majority of women with
this diagnosis will die from recurrence of their disease. Targeted therapies, in the form of …

Ovarian cancer is the leading cause of death in women with gynecological malignancies
and overall survival for patients with advanced epithelial ovarian cancer (EOC) remains …

Ovarian cancer is the leading cause of death from gynaecological malignancies in the
Western world. Despite the evolution of surgical techniques and meticulously designed …

Unfortunately, ovarian cancer is still diagnosed most often only in an advanced stage and is
also the most lethal gynecological cancer. Another problem is the fact that treated patients …

Epithelial ovarian cancer remains a major women′ s health problem due to its high
lethality. Despite great efforts to develop effective prevention and early detection strategies …

Despite advances in surgery and chemotherapy, less than 20% of patients with stage III or IV
ovarian cancer survive long-term. In the past, cytotoxic regimens have been developed …

Objective As a result of relevant achievements in the field of translational research, several
active drugs and multiple biological targets are available in ovarian cancer (OC). In this …